|
1
|
Effect of nesiritide in patients with acute decompensated heart failure.
|
N Engl J Med
|
2011
|
7.62
|
|
2
|
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators.
|
N Engl J Med
|
1996
|
5.94
|
|
3
|
Randomised trials of secondary prevention programmes in coronary heart disease: systematic review.
|
BMJ
|
2001
|
5.63
|
|
4
|
A systematic review of randomized trials of disease management programs in heart failure.
|
Am J Med
|
2001
|
5.38
|
|
5
|
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.
|
Lancet
|
1999
|
4.36
|
|
6
|
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
|
N Engl J Med
|
1995
|
4.29
|
|
7
|
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction.
|
N Engl J Med
|
2000
|
4.19
|
|
8
|
Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
|
N Engl J Med
|
1995
|
3.69
|
|
9
|
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators.
|
Circulation
|
2000
|
3.61
|
|
10
|
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.
|
Circulation
|
1999
|
3.06
|
|
11
|
Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial.
|
Circulation
|
2000
|
2.49
|
|
12
|
Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries.
|
CMAJ
|
1997
|
2.46
|
|
13
|
Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators.
|
Clin Chem
|
1998
|
2.27
|
|
14
|
A comparison of U.S. and Canadian cardiac catheterization practices in detecting severe coronary artery disease after myocardial infarction: efficiency, yield and long-term implications.
|
J Am Coll Cardiol
|
1999
|
2.24
|
|
15
|
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study.
|
Lancet
|
2001
|
2.23
|
|
16
|
Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries.
|
J Am Coll Cardiol
|
1995
|
2.12
|
|
17
|
Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators.
|
Circulation
|
1998
|
2.09
|
|
18
|
One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators.
|
Circulation
|
1996
|
2.03
|
|
19
|
Thrombolysis in unstable angina. Randomized double-blind trial of t-PA and placebo.
|
Circulation
|
1992
|
1.97
|
|
20
|
Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators.
|
J Am Coll Cardiol
|
1996
|
1.91
|
|
21
|
Detection of silent myocardial ischemia in diabetes mellitus.
|
Am J Cardiol
|
1991
|
1.78
|
|
22
|
Insights into the contemporary epidemiology and outpatient management of congestive heart failure.
|
Am Heart J
|
1999
|
1.75
|
|
23
|
Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokinase and TPA for Occluded Arteries.
|
Circulation
|
1996
|
1.66
|
|
24
|
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes.
|
Eur Heart J
|
2004
|
1.59
|
|
25
|
Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA.
|
Eur Heart J
|
2001
|
1.58
|
|
26
|
Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries.
|
Eur Heart J
|
1999
|
1.57
|
|
27
|
A mammalian mitochondrial serine transfer RNA lacking the "dihydrouridine" loop and stem.
|
Nucleic Acids Res
|
1980
|
1.56
|
|
28
|
Time to treatment influences the impact of ST-segment resolution on one-year prognosis: insights from the assessment of the safety and efficacy of a new thrombolytic (ASSENT-2) trial.
|
Circulation
|
2001
|
1.56
|
|
29
|
Fibrillar collagen and remodeling of dilated canine left ventricle.
|
Circulation
|
1990
|
1.55
|
|
30
|
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial.
|
Eur Heart J
|
2000
|
1.55
|
|
31
|
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation.
|
Heart
|
2008
|
1.54
|
|
32
|
Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial.
|
Eur Heart J
|
1996
|
1.52
|
|
33
|
Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non-Q wave myocardial infarction. (LATE Study Investigators)
|
J Am Coll Cardiol
|
1996
|
1.48
|
|
34
|
Temporal evolution in the management of acute ST elevation myocardial infarction: the seven-year GUSTO experience from canada and the united states. The North American GUSTO-I and GUSTO-III investigators.
|
Can J Cardiol
|
2000
|
1.47
|
|
35
|
Coronary patency, infarct size and left ventricular function after thrombolytic therapy for acute myocardial infarction: results from the tissue plasminogen activator: Toronto (TPAT) placebo-controlled trial. TPAT Study Group.
|
J Am Coll Cardiol
|
1991
|
1.45
|
|
36
|
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.
|
J Thromb Haemost
|
2005
|
1.42
|
|
37
|
Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial.
|
Eur Heart J
|
2003
|
1.42
|
|
38
|
Angiographic morphology in unstable angina pectoris.
|
Am J Cardiol
|
1988
|
1.42
|
|
39
|
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction.
|
Circulation
|
2003
|
1.41
|
|
40
|
Remodeling and reparation of the cardiovascular system.
|
J Am Coll Cardiol
|
1992
|
1.41
|
|
41
|
Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission?
|
Eur Heart J
|
2003
|
1.40
|
|
42
|
Heparin in acute coronary disease--requiem for a heavyweight?
|
N Engl J Med
|
1997
|
1.39
|
|
43
|
Acute reduction of lipoprotein(a) by tissue-type plasminogen activator.
|
Circulation
|
1992
|
1.39
|
|
44
|
Management of asymptomatic chronic aortic regurgitation with left ventricular dysfunction: a decision analysis.
|
J Gen Intern Med
|
1990
|
1.39
|
|
45
|
Adverse effects of corticosteroids on the cardiovascular system.
|
Can J Cardiol
|
2000
|
1.39
|
|
46
|
Prognosis in medically stabilized unstable angina: early Holter ST-segment monitoring compared with predischarge exercise thallium tomography.
|
Ann Intern Med
|
1990
|
1.38
|
|
47
|
Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure.
|
Circulation
|
1986
|
1.38
|
|
48
|
Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy.
|
CMAJ
|
1989
|
1.36
|
|
49
|
Comparison of the appropriateness of coronary angiography and coronary artery bypass graft surgery between Canada and New York State.
|
JAMA
|
1994
|
1.35
|
|
50
|
The influence of changes in blood volume on angina pectoris. A study of the effect of phlebotomy.
|
Circulation
|
1970
|
1.29
|
|
51
|
Chronic false aneurysms of the left ventricle: management revisited.
|
Can J Cardiol
|
1994
|
1.28
|
|
52
|
Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network.
|
J Am Coll Cardiol
|
2001
|
1.27
|
|
53
|
Swallow syncope.
|
Can Med Assoc J
|
1985
|
1.24
|
|
54
|
Blood levels after sublingual nitroglycerin.
|
Circulation
|
1979
|
1.22
|
|
55
|
Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
|
JAMA
|
1995
|
1.21
|
|
56
|
Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators.
|
Circulation
|
1997
|
1.17
|
|
57
|
27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management.
|
J Am Coll Cardiol
|
1996
|
1.17
|
|
58
|
Serum magnesium and potassium in acute myocardial infarction. Influence on ventricular arrhythmias.
|
Arch Intern Med
|
1987
|
1.16
|
|
59
|
Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis.
|
Circ Res
|
1994
|
1.16
|
|
60
|
Vasodilator therapy in acute myocardial infarction. A comparison of sodium nitroprusside and nitroglycerin.
|
Circulation
|
1975
|
1.11
|
|
61
|
Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.
|
Am J Cardiol
|
1999
|
1.10
|
|
62
|
Pharmacokinetic-hemodynamic studies of nitroglycerin ointment in congestive heart failure.
|
Am J Cardiol
|
1980
|
1.09
|
|
63
|
Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy.
|
Circulation
|
2001
|
1.07
|
|
64
|
A predictive index for length of stay in the intensive care unit following cardiac surgery.
|
CMAJ
|
1994
|
1.04
|
|
65
|
Effect of nitroglycerin ointment on the clinical and hemodynamic response to exercise.
|
Am J Cardiol
|
1976
|
1.04
|
|
66
|
Differences in the treatment of myocardial infarction between the United States and Canada. A survey of physicians in the GUSTO trial.
|
Med Care
|
1995
|
1.03
|
|
67
|
Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues.
|
Can J Physiol Pharmacol
|
1987
|
1.02
|
|
68
|
Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial.
|
Circulation
|
2000
|
1.02
|
|
69
|
Coronary revascularization after thrombolytic therapy for myocardial infarction: what caseloads could Canadian centres face?
|
CMAJ
|
1989
|
1.01
|
|
70
|
Amiodarone hepatotoxicity simulating alcoholic liver disease.
|
N Engl J Med
|
1984
|
1.01
|
|
71
|
Prinzmetal's angina, normal coronary arteries and pericarditis.
|
Can Med Assoc J
|
1978
|
1.00
|
|
72
|
Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia.
|
J Am Coll Cardiol
|
1995
|
0.98
|
|
73
|
Canadian-American differences in the management of acute coronary syndromes in the GUSTO IIb trial: one-year follow-up of patients without ST-segment elevation. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) II Investigators.
|
Circulation
|
2000
|
0.98
|
|
74
|
Early recovery from heart failure: insights into the pathogenesis of experimental chronic pacing-induced heart failure.
|
J Lab Clin Med
|
1988
|
0.96
|
|
75
|
The complications of brachial arteriotomy.
|
J Thorac Cardiovasc Surg
|
1971
|
0.95
|
|
76
|
Pharmacokinetic-hemodynamic studies of intravenous nitroglycerin in congestive cardiac failure.
|
Circulation
|
1980
|
0.95
|
|
77
|
ST segment shift in unstable angina: pathophysiology and association with coronary anatomy and hospital outcome.
|
J Am Coll Cardiol
|
1989
|
0.94
|
|
78
|
Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival.
|
Arch Intern Med
|
2001
|
0.94
|
|
79
|
Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction.
|
J Am Coll Cardiol
|
2000
|
0.94
|
|
80
|
Arterial-venous nitroglycerin gradient during intravenous infusion in man.
|
Circulation
|
1982
|
0.93
|
|
81
|
Endothelium modulation of the effects of nitroglycerin on blood vessels from dogs with pacing-induced heart failure.
|
Br J Pharmacol
|
1990
|
0.93
|
|
82
|
Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.
|
Circulation
|
2000
|
0.93
|
|
83
|
Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials.
|
Circulation
|
2001
|
0.93
|
|
84
|
Rapid ventricular pacing of dogs to heart failure: biochemical and physiological studies.
|
Can J Physiol Pharmacol
|
1990
|
0.93
|
|
85
|
Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy.
|
J Am Coll Cardiol
|
1998
|
0.92
|
|
86
|
Incidence and impact on outcome of streptokinase allergy in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA in Occluded Coronary Arteries.
|
Am J Cardiol
|
1997
|
0.92
|
|
87
|
Usefulness of ischemic response to mental stress in predicting silent myocardial ischemia during ambulatory monitoring.
|
Am J Cardiol
|
1995
|
0.91
|
|
88
|
Steady state pharmacokinetic haemodynamic studies of intravenous nitroglycerin in congestive cardiac failure.
|
Br J Clin Pharmacol
|
1983
|
0.91
|
|
89
|
Biases in the measurement of arterial pressure.
|
Crit Care Med
|
1984
|
0.90
|
|
90
|
Pathophysiology and time course of silent myocardial ischaemia during mental stress: clinical, anatomical, and physiological correlates.
|
Br Heart J
|
1995
|
0.89
|
|
91
|
Nuggets, pearls, and vignettes of master heart failure clinicians. Part 2-the physical examination.
|
Congest Heart Fail
|
2002
|
0.89
|
|
92
|
Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes.
|
J Am Coll Cardiol
|
2001
|
0.88
|
|
93
|
Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
|
J Am Coll Cardiol
|
1995
|
0.88
|
|
94
|
Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries.
|
Am J Cardiol
|
1999
|
0.88
|
|
95
|
Evaluation of indices of left ventricular contractility and relaxation in evolving canine experimental heart failure.
|
Cardiovasc Res
|
1992
|
0.88
|
|
96
|
Intracoronary thrombus and complex morphology in unstable angina. Relation to timing of angiography and in-hospital cardiac events.
|
Circulation
|
1989
|
0.87
|
|
97
|
Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries.
|
J Am Coll Cardiol
|
1998
|
0.87
|
|
98
|
Clinical trial Data and Safety Monitoring Boards. The search for a constitution.
|
Circulation
|
1995
|
0.87
|
|
99
|
Progress in the treatment of acute coronary syndromes: a 50-year perspective (1950-2000).
|
Circulation
|
2000
|
0.87
|
|
100
|
Tolerance to organic nitrates: clinical and experimental perspectives.
|
Am J Med
|
1983
|
0.86
|
|
101
|
Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trial.
|
Heart
|
2005
|
0.86
|
|
102
|
Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trial.
|
J Am Coll Cardiol
|
1998
|
0.86
|
|
103
|
Nitroglycerin ointment in acute myocardial infarction.
|
Am J Cardiol
|
1976
|
0.86
|
|
104
|
Left ventricular myocardial blood flow, metabolism, and effects of treatment with enalapril: further insights into the mechanisms of canine experimental pacing-induced heart failure.
|
J Lab Clin Med
|
1993
|
0.85
|
|
105
|
Effects of propranolol on the hemodynamic, coronary sinus blood flow and myocardial metabolic response to atrial pacing.
|
Am J Cardiol
|
1977
|
0.85
|
|
106
|
Alterations in serum sodium in relation to atrial natriuretic factor and other neuroendocrine variables in experimental pacing-induced heart failure.
|
J Am Coll Cardiol
|
1989
|
0.85
|
|
107
|
Endothelial nitric oxide synthase increases in left atria of dogs with pacing-induced heart failure.
|
Am J Physiol
|
1998
|
0.85
|
|
108
|
Perspectives on large-scale cardiovascular clinical trials for the new millennium. The Virtual Coordinating Center for Global Collaborative Cardiovascular Research (VIGOUR) Group.
|
Circulation
|
1997
|
0.84
|
|
109
|
Hemodynamic evaluation of glucagon in symptomatic heart disease.
|
Circulation
|
1971
|
0.83
|
|
110
|
Effects of thrombolytic therapy administered 6 to 24 hours after myocardial infarction on the signal-averaged ECG. Results of a multicenter randomized trial. LATE Ancillary Study Investigators. Late Assessment of Thrombolytic Efficacy.
|
Circulation
|
1994
|
0.83
|
|
111
|
Pathophysiology and prognostic significance of Holter-detected ST segment depression after myocardial infarction. The Tissue Plasminogen Activator: Toronto (TPAT) Study Group.
|
J Am Coll Cardiol
|
1992
|
0.83
|
|
112
|
Etiology and differential diagnosis of acute mitral regurgitation.
|
Prog Cardiovasc Dis
|
1971
|
0.83
|
|
113
|
Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making.
|
Eur Heart J
|
2003
|
0.82
|
|
114
|
Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators.
|
J Card Fail
|
1998
|
0.82
|
|
115
|
Assessment of ventricular function in coronary artery disease by means of atrial pacing and exercise.
|
Am J Cardiol
|
1970
|
0.81
|
|
116
|
A tale of two countries: Insights from the differences in Canadian/American patterns of care for patients with acute coronary syndromes.
|
Am Heart J
|
2001
|
0.80
|
|
117
|
Influence of skin site on bioavailability of nitroglycerin ointment in congestive heart failure.
|
Am J Med
|
1986
|
0.80
|
|
118
|
Response of atrial natriuretic factor to acute and chronic increases of atrial pressures in experimental heart failure in dogs. Role of changes in heart rate, atrial dimension, and cardiac tissue concentration.
|
Circulation
|
1991
|
0.80
|
|
119
|
Therapeutic exercise for individuals with heart failure: special attention to older women with heart failure.
|
J Card Fail
|
2004
|
0.80
|
|
120
|
Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group.
|
Eur J Heart Fail
|
2000
|
0.80
|
|
121
|
Recovery from heart failure: structural and functional analysis in a canine model.
|
Can J Physiol Pharmacol
|
1988
|
0.80
|
|
122
|
Detection of silent ischemia adds to the prognostic value of coronary anatomy and left ventricular function in predicting outcome in unstable angina patients.
|
Can J Cardiol
|
1995
|
0.80
|
|
123
|
Reverse redistribution on exercise thallium scintigraphy: relationship to coronary patency and ventricular function after myocardial infarction.
|
Can J Cardiol
|
1992
|
0.80
|
|
124
|
Beyond drug therapy: nonpharmacologic care of the patient with advanced heart failure.
|
Am Heart J
|
1998
|
0.80
|
|
125
|
N-acetylcysteine does not modify nitroglycerin-induced tolerance in canine vascular rings.
|
J Cardiovasc Pharmacol
|
1987
|
0.80
|
|
126
|
Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators.
|
Circulation
|
1998
|
0.80
|
|
127
|
Hemodynamic monitoring in the critically ill patient: overview of symposium.
|
Can Med Assoc J
|
1979
|
0.79
|
|
128
|
Clinical trials:randomization before consent.
|
Biomedicine
|
1981
|
0.79
|
|
129
|
Abnormalities of cardiac sympathetic function in pacing-induced heart failure as assessed by [123I]metaiodobenzylguanidine scintigraphy.
|
Circulation
|
1994
|
0.78
|
|
130
|
Pursuing progress in acute coronary syndromes.
|
Circulation
|
1999
|
0.78
|
|
131
|
Relation between baseline risk and treatment decisions in non-ST elevation acute coronary syndromes: an examination of international practice patterns.
|
Heart
|
2005
|
0.78
|
|
132
|
Atrial natriuretic factor: pharmacokinetics and cyclic GMP response in relation to biologic effects in severe heart failure.
|
J Cardiovasc Pharmacol
|
1992
|
0.78
|
|
133
|
Psychiatric morbidity during the early phase of coronary care for myocardial infarction: association with cardiac diagnosis and outcome.
|
Can J Psychiatry
|
1992
|
0.78
|
|
134
|
Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
|
Eur Heart J
|
1998
|
0.78
|
|
135
|
Specific and non-specific measurements of tissue angiotensin II cascade members.
|
J Pharm Biomed Anal
|
2001
|
0.78
|
|
136
|
Relation of angiographic detected intracoronary thrombus and silent myocardial ischemia in unstable angina pectoris.
|
Am J Cardiol
|
1990
|
0.78
|
|
137
|
Inhibitory role of the coronary arterial endothelium to alpha-adrenergic stimulation in experimental heart failure.
|
Circ Res
|
1991
|
0.78
|
|
138
|
Pharmacokinetic-hemodynamic studies of transdermal nitroglycerin in congestive heart failure.
|
J Am Coll Cardiol
|
1987
|
0.78
|
|
139
|
Role of resting thallium201 perfusion in predicting coronary anatomy, left ventricular wall motion, and hospital outcome in unstable angina pectoris.
|
Am Heart J
|
1989
|
0.77
|
|
140
|
Benefit of angiographic spontaneous reperfusion in STEMI: does it extend to diabetic patients?
|
Heart
|
2009
|
0.77
|
|
141
|
Comparative effects of lidocaine and procainamide on acutely impaired hemodynamics.
|
Am J Med
|
1976
|
0.77
|
|
142
|
Pharmacokinetic-hemodynamic studies of disopyramide.
|
J Cardiovasc Pharmacol
|
1984
|
0.77
|
|
143
|
Letter: Swan-Ganz catheter repair.
|
Circulation
|
1976
|
0.77
|
|
144
|
Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries.
|
Am J Cardiol
|
1998
|
0.77
|
|
145
|
Calcium antagonists: new therapy for congestive heart failure?
|
Chest
|
1987
|
0.77
|
|
146
|
Rapid disappearance of nitroglycerin following incubation with human blood.
|
Can J Physiol Pharmacol
|
1980
|
0.77
|
|
147
|
It's a matter of time: contemporary pre-hospital management of acute ST elevation myocardial infarction.
|
Heart
|
2005
|
0.77
|
|
148
|
Left ventricular remodelling and disparate changes in contractility and relaxation during the development of and recovery from experimental heart failure.
|
Cardiovasc Res
|
1994
|
0.77
|
|
149
|
Hemodynamic evaluation of rate augmentation produced by atrial pacing and isoproterenol in the early postoperative phase of cardiac valve surgery.
|
Circulation
|
1971
|
0.77
|
|
150
|
Pharmacokinetics, hemodynamic, renal, and neurohormonal effects of atrial natriuretic factor in experimental heart failure.
|
Clin Invest Med
|
1990
|
0.77
|
|
151
|
Cardiac depression by intravenous disopyramide in patients with left ventricular dysfunction.
|
Am J Med
|
1980
|
0.76
|
|
152
|
Ultrastructural studies of unstable angina in living man.
|
Mod Pathol
|
1991
|
0.76
|
|
153
|
Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.
|
J Am Coll Cardiol
|
1998
|
0.76
|
|
154
|
Spectrum of ischemic heart disease and the role of biochemical markers.
|
Clin Lab Med
|
1997
|
0.76
|
|
155
|
Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative.
|
Can J Cardiol
|
1997
|
0.76
|
|
156
|
Plasma concentration time course and pharmacological effects of a standardized oral amiodarone dosing regimen in humans.
|
Can J Cardiol
|
1991
|
0.76
|
|
157
|
Cardiac and muscle fatigue due to relative functional overload induced by excessive stimulation, hypersensitive excitation-contraction coupling, or diminished performance capacity correlates with sarcoplasmic reticulum failure.
|
Can J Physiol Pharmacol
|
1991
|
0.76
|
|
158
|
Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention.
|
Am J Cardiol
|
2001
|
0.76
|
|
159
|
Rapid high-performance liquid chromatographic analysis of amiodarone and N-desethyl-amiodarone in serum.
|
Can J Physiol Pharmacol
|
1983
|
0.76
|
|
160
|
Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.
|
J Thromb Haemost
|
2004
|
0.76
|
|
161
|
Beta adrenoceptor recovery after heart failure in the dog.
|
Cardiovasc Res
|
1993
|
0.76
|
|
162
|
Pathophysiological role of changing atrial size and pressure in modulation of atrial natriuretic factor during evolving experimental heart failure.
|
Cardiovasc Res
|
1990
|
0.76
|
|
163
|
Age-dependent augmentation of cardiac endothelial NOS in a genetic rat model of heart failure.
|
Am J Physiol
|
1997
|
0.76
|
|
164
|
Sequential echocardiographic-Doppler assessment of left ventricular remodelling and mitral regurgitation during evolving experimental heart failure.
|
Cardiovasc Res
|
1991
|
0.76
|
|
165
|
Dual natriuretic peptide system in experimental heart failure.
|
J Am Coll Cardiol
|
1993
|
0.76
|
|
166
|
Investigation of the role of prostaglandins in nitroglycerin-induced relaxation of isolated rabbit blood vessels.
|
Can J Physiol Pharmacol
|
1983
|
0.76
|
|
167
|
Treatment of postural hypotension with aerosol ergotamine.
|
CMAJ
|
1988
|
0.75
|
|
168
|
Novel methodology for echocardiographic quantification of cardiac shape.
|
Can J Cardiol
|
1997
|
0.75
|
|
169
|
Congestive heart failure.
|
CMAJ
|
1988
|
0.75
|
|
170
|
Momento mori.
|
Hastings Cent Rep
|
1994
|
0.75
|
|
171
|
Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease.
|
Circulation
|
2000
|
0.75
|
|
172
|
Intracranial haemorrhage with bolus thrombolytic agents.
|
Lancet
|
2000
|
0.75
|
|
173
|
Toward improved coronary artery revascularization: is this as good as it gets?
|
CMAJ
|
1998
|
0.75
|
|
174
|
Preservation of pre-excitation despite acute myocardial infarction complicated by complete heart block.
|
Can Med Assoc J
|
1978
|
0.75
|
|
175
|
Maximizing the benefits of thrombolytic therapy for acute myocardial infarction.
|
CMAJ
|
1995
|
0.75
|
|
176
|
Thrombolytic therapy and unstable angina.
|
Circulation
|
1992
|
0.75
|
|
177
|
How does intermittent pacing modify the response to rapid ventricular pacing in experimental heart failure?
|
J Card Fail
|
1995
|
0.75
|
|
178
|
Behaviour and coronary artery disease: is this the missing link?
|
Can Med Assoc J
|
1978
|
0.75
|
|
179
|
Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure.
|
Can Med Assoc J
|
1979
|
0.75
|
|
180
|
Hemolytic anemia following insertion of Ionescu-Shiley mitral valve bioprosthesis.
|
Can Med Assoc J
|
1984
|
0.75
|
|
181
|
Reperfusion synergism: will it be both sustained and safe?
|
Eur Heart J
|
2000
|
0.75
|
|
182
|
Progressive left ventricular dysfunction and remodeling after myocardial infarction.
|
Circulation
|
1993
|
0.75
|
|
183
|
Protection of ischemic myocardium.
|
Can Med Assoc J
|
1977
|
0.75
|
|
184
|
On-line microcomputer system for analysis of precordial maps.
|
J Electrocardiol
|
1982
|
0.75
|
|
185
|
Clinical lessons learned from experimental heart failure.
|
Int J Cardiol
|
1989
|
0.75
|
|
186
|
Collaborative cardiovascular clinical research in Canada: coming of age.
|
Can J Cardiol
|
1995
|
0.75
|
|
187
|
Effects of hemoperfusion during percutaneous transluminal coronary angioplasty on left ventricular function.
|
Am J Cardiol
|
1991
|
0.75
|
|
188
|
Graded exercise testing following thrombolytic therapy for acute myocardial infarction: the importance of timing and infarct location. TPAT Study Group.
|
Can J Cardiol
|
1994
|
0.75
|
|
189
|
BME defines public policy in physician self-referral.
|
N J Med
|
1997
|
0.75
|
|
190
|
Recovery of attenuated baroreflex sensitivity in conscious dogs after reversal of pacing induced heart failure.
|
Cardiovasc Res
|
1994
|
0.75
|
|
191
|
Letter: Discovery of paravalvular defects.
|
J Thorac Cardiovasc Surg
|
1974
|
0.75
|
|
192
|
Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial.
|
Am J Cardiol
|
2001
|
0.75
|
|
193
|
Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.
|
Circulation
|
2001
|
0.75
|
|
194
|
The battle for physicians' rights.
|
N J Med
|
1998
|
0.75
|
|
195
|
Sex-related difference in the metabolism of isosorbide dinitrate following incubation in human blood.
|
Biochem Pharmacol
|
1983
|
0.75
|
|
196
|
Noradrenaline biosynthesis and metabolism during development and recovery from pacing-induced heart failure in the dog.
|
Can J Physiol Pharmacol
|
1994
|
0.75
|
|
197
|
Quantification of myocardial infarction: template model for serial creatine kinase analysis.
|
Circulation
|
1979
|
0.75
|
|
198
|
Response of atrial natriuretic factor to postural change in patients with heart failure versus subjects with normal hemodynamics.
|
J Am Coll Cardiol
|
1990
|
0.75
|
|
199
|
Hemodynamic monitoring in critically ill patients.
|
Heart Lung
|
1981
|
0.75
|
|
200
|
Comparison of rest and exercise thallium-201 kinetics in man and implications for quantitation.
|
Am J Physiol Imaging
|
1989
|
0.75
|
|
201
|
Aggressive clinical pattern of angina at restenosis following coronary angioplasty in unstable angina.
|
Am Heart J
|
1992
|
0.75
|
|
202
|
MSNJ's expert panel on late-term abortion. Medical Society of New Jersey.
|
N J Med
|
1997
|
0.75
|
|
203
|
Endothelium-dependent relaxations in canine coronary arteries are enhanced in early heart failure and persist in recovery.
|
Can J Physiol Pharmacol
|
1994
|
0.75
|
|
204
|
Temporal alterations in peripheral vascular responsiveness during both the development and recovery from pacing-induced heart failure.
|
J Cardiovasc Pharmacol
|
1992
|
0.75
|
|
205
|
Investigations into the role of sulfhydryl groups in the mechanism of action of the nitrates.
|
Can J Physiol Pharmacol
|
1982
|
0.75
|
|
206
|
Postcoronary thrombolysis management.
|
Can J Cardiol
|
1993
|
0.75
|
|
207
|
Pharmacokinetic-hemodynamic studies of nitroglycerin in congestive cardiac failure.
|
Nouv Presse Med
|
1980
|
0.75
|
|
208
|
Sequential changes in atrial pressures, dimensions, and plasma atrial natriuretic factor concentrations during volume loading in hemodynamically normal human subjects.
|
J Lab Clin Med
|
1991
|
0.75
|
|
209
|
Reproducibility of the pharmacokinetic-hemodynamic response to nitroglycerin in the dog: a model for studying the effects of chronic treatment.
|
J Pharmacol Methods
|
1984
|
0.75
|
|
210
|
Plasma endothelin in chronic heart failure.
|
Circulation
|
1993
|
0.75
|
|
211
|
Does a hypertonic saline load predict fluid retention in pacing induced heart failure?
|
Cardiovasc Res
|
1997
|
0.75
|
|
212
|
Physiological effects of synthetic atrial natriuretic factor in normal conscious dogs.
|
Clin Invest Med
|
1988
|
0.75
|
|
213
|
A new design for randomized trials.
|
N Engl J Med
|
1979
|
0.75
|
|
214
|
Measurement of angiotensin II: use of two injectors to minimize HPLC shadowing.
|
Peptides
|
1994
|
0.75
|
|
215
|
Influence of ecdysterone on molting in Palaemonetes.
|
Gen Comp Endocrinol
|
1972
|
0.75
|
|
216
|
Disposition of amiodarone and its proximate metabolite, desethylamiodarone, in the dog for oral administration of single-dose and short-term drug regimens.
|
Drug Metab Dispos
|
1991
|
0.75
|
|
217
|
Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
|
Eur Heart J
|
1995
|
0.75
|
|
218
|
Plasma and cardiac tissue atrial and brain natriuretic peptides in experimental heart failure.
|
J Am Coll Cardiol
|
1996
|
0.75
|
|
219
|
A new method for hemodynamic and echocardiographic assessment of conscious dogs: comparison with thiopental-morphine anaesthesia.
|
Clin Invest Med
|
1990
|
0.75
|
|
220
|
From Quinlan to Jobes: the courts and the PVS patient.
|
Hastings Cent Rep
|
1988
|
0.75
|
|
221
|
Intravenous nisoldipine in severe congestive heart failure.
|
J Cardiovasc Pharmacol
|
1988
|
0.75
|
|
222
|
The 49th parallel: how much latitude?
|
J Am Coll Cardiol
|
1995
|
0.75
|
|
223
|
New dose regimens for coronary thrombolysis.
|
Can J Cardiol
|
1993
|
0.75
|
|
224
|
Comment: more thoughts on senility.
|
Gerontologist
|
1978
|
0.75
|
|
225
|
Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial).
|
Am J Cardiol
|
2000
|
0.75
|
|
226
|
Impact of tissue plasminogen activator and heparin versus heparin alone on quantitative coronary angiographic findings in myocardial infarction. The Toronto Tissue Plasminogen Activator Trial Study Group.
|
Am J Cardiol
|
1993
|
0.75
|
|
227
|
Does ambulatory monitoring contribute to exercise testing and myocardial perfusion scintigraphy in the prediction of the extent of coronary artery disease in stable angina?
|
Am J Cardiol
|
1994
|
0.75
|
|
228
|
From thrombolytic megatrials to clinical policy-making: facing the facts.
|
Can J Cardiol
|
1995
|
0.75
|
|
229
|
Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
|
Am Heart J
|
1998
|
0.75
|
|
230
|
Anticoagulant therapy in unstable angina.
|
Cardiol Clin
|
1999
|
0.75
|
|
231
|
Impact of enalapril therapy on in vitro coronary artery responsiveness in pacing-induced heart failure.
|
Can J Physiol Pharmacol
|
1992
|
0.75
|
|
232
|
Absence of metabolite formation during nitroglycerin-induced relaxation of isolated blood vessels.
|
Mol Pharmacol
|
1980
|
0.75
|
|
233
|
Supraventricular tachycardia terminated by external mechanical stimulation: a case of "pothole conversion".
|
Pacing Clin Electrophysiol
|
1999
|
0.75
|
|
234
|
Myocardial energetics and blood flow in acute rapid ventricular pacing.
|
Can J Physiol Pharmacol
|
1994
|
0.75
|
|
235
|
Biatrial appendage hypertrophy but not ventricular hypertrophy: a unique feature of canine pacing-induced heart failure.
|
J Card Fail
|
1996
|
0.75
|
|
236
|
Lipoprotein(a) and silent myocardial ischemia in IDDM.
|
Diabetes Care
|
1994
|
0.75
|
|
237
|
Lipoprotein(a) and apolipoproteins B and A-I after acute myocardial infarction.
|
Can J Cardiol
|
1995
|
0.75
|
|
238
|
Novel vascular effects of isoprenaline following pacing-induced heart failure in the dog.
|
Eur J Pharmacol
|
1991
|
0.75
|
|
239
|
A comparative evaluation of hemodynamic and neurohumoral effects of nitroglycerin and nifedipine in congestive heart failure.
|
Am J Cardiol
|
1987
|
0.75
|
|
240
|
Ethacrynic acid: acute hemodynamic effects and influence on the in vivo and in vitro response to nitroglycerin in the dog.
|
J Cardiovasc Pharmacol
|
1985
|
0.75
|
|
241
|
Frequency of transient reductions in left ventricular ejection fraction at rest in coronary artery disease.
|
Am J Cardiol
|
1994
|
0.75
|
|
242
|
Sarcoplasmic reticulum Ca-release channel and ATP-synthesis activities are early myocardial markers of heart failure produced by rapid ventricular pacing in dogs.
|
Can J Physiol Pharmacol
|
1994
|
0.75
|
|
243
|
The courts and the PVS patient.
|
N J Med
|
1989
|
0.75
|
|
244
|
Determination of disopyramide and mono-N-desisopropyl-disopyramide in serum by gas-liquid chromatography with nitrogen-selective detection.
|
J Pharmacol Methods
|
1983
|
0.75
|
|
245
|
Usefulness of exercise electrocardiography and thallium scintigraphy in unstable angina pectoris in predicting the extent and severity of coronary artery disease.
|
Am J Cardiol
|
1988
|
0.75
|
|
246
|
Alpha 1-adrenoceptor activity in arterial smooth muscle following congestive heart failure.
|
Can J Physiol Pharmacol
|
1989
|
0.75
|
|
247
|
Elevated left atrial pressure does not cause left-to-right shunting after mitral balloon valvuloplasty.
|
Cathet Cardiovasc Diagn
|
1991
|
0.75
|
|
248
|
Improving end-of-life care for New Jerseyans.
|
N J Med
|
1996
|
0.75
|
|
249
|
Pacing-induced heart failure in the dog: evaluation of peripheral vascular alpha-adrenoceptor subtypes.
|
J Cardiovasc Pharmacol
|
1990
|
0.75
|
|
250
|
Hemodynamic clues to the discrepancy between the angiographic and intraoperative assessment of aortic regurgitation.
|
J Thorac Cardiovasc Surg
|
1973
|
0.75
|
|
251
|
New Jersey's "Granny Doe" squad: arguments about mechanisms for protection of vulnerable patients.
|
Law Med Health Care
|
1989
|
0.75
|
|
252
|
The feasibility of physician unions and collective bargaining.
|
N J Med
|
1997
|
0.75
|
|
253
|
Important patient subgroups in thrombolytic therapy.
|
Can J Cardiol
|
1993
|
0.75
|
|
254
|
The spectrum of unstable angina: prognostic role of serum creatine kinase determination.
|
Am J Cardiol
|
1982
|
0.75
|
|
255
|
Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial.
|
Eur Heart J
|
2002
|
0.75
|